Connor Clark & Lunn Investment Management Ltd. bought a new stake in Phreesia, Inc. (NYSE:PHR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 37,052 shares of the company's stock, valued at approximately $932,000. Connor Clark & Lunn Investment Management Ltd. owned 0.06% of Phreesia as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. PNC Financial Services Group Inc. grew its position in Phreesia by 9.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 22,445 shares of the company's stock valued at $565,000 after acquiring an additional 2,008 shares during the period. Raymond James Financial Inc. purchased a new stake in Phreesia during the fourth quarter worth approximately $379,000. Proficio Capital Partners LLC acquired a new stake in shares of Phreesia in the fourth quarter worth $377,000. M&T Bank Corp increased its position in shares of Phreesia by 56.4% in the fourth quarter. M&T Bank Corp now owns 54,939 shares of the company's stock worth $1,382,000 after acquiring an additional 19,812 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Phreesia by 10.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 493,448 shares of the company's stock valued at $12,415,000 after acquiring an additional 46,209 shares during the period. Institutional investors and hedge funds own 92.10% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on PHR. KeyCorp increased their price target on Phreesia from $28.00 to $30.00 and gave the company an "overweight" rating in a report on Wednesday, January 8th. Royal Bank of Canada upgraded Phreesia from a "sector perform" rating to an "outperform" rating and raised their target price for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Canaccord Genuity Group upped their price target on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Citigroup lifted their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, January 10th. Finally, JMP Securities restated a "market outperform" rating and issued a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $31.33.
View Our Latest Stock Analysis on Phreesia
Phreesia Stock Performance
PHR stock traded up $0.65 during mid-day trading on Monday, reaching $28.11. The company had a trading volume of 556,397 shares, compared to its average volume of 417,221. The stock's 50-day simple moving average is $27.33 and its two-hundred day simple moving average is $24.07. The stock has a market capitalization of $1.65 billion, a P/E ratio of -19.12 and a beta of 1.03. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53.
Insider Buying and Selling at Phreesia
In related news, COO Evan Roberts sold 3,519 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $30.06, for a total value of $105,781.14. Following the completion of the transaction, the chief operating officer now directly owns 741,197 shares of the company's stock, valued at $22,280,381.82. This represents a 0.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 3,496 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $25.32, for a total value of $88,518.72. Following the completion of the sale, the general counsel now owns 139,134 shares in the company, valued at approximately $3,522,872.88. This represents a 2.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 162,442 shares of company stock valued at $4,611,300 in the last ninety days. Company insiders own 5.80% of the company's stock.
Phreesia Profile
(
Free Report)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Further Reading
Before you consider Phreesia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.
While Phreesia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
